Drug development is often constrained by development timelines that can extend 10–15 years from discovery to clinical implementation. While these timelines are intended to ensure safety and rigor, they frequently conflict with the urgency faced by patients with life-threatening diseases. A first-principles approach to translational medicine challenges the assumption that current development systems are inevitable and instead reexamines how such systems might be designed if built from fundamental biological, economic, and clinical realities. By deconstructing traditional development models into their basic components, opportunities emerge to redesign the translational ecosystem around speed of learning, integrated capabilities, and alignment with patient need. This perspective explores how integrated research environments, proximity between clinicians and scientists, and intelligent engagement with global regulatory frameworks can accelerate the translation of scientific insight into clinical impact. Ultimately, rethinking the architecture of translational medicine may be as important as advances in biology itself in determining how quickly new therapies reach patients.
- Open Access
- Commentary
A First-Principles Framework for Accelerating Translational Medicine
- Edward Clay 1,2,
- Annette Marleau 1,*
Author Information
Received: 24 Apr 2026 | Revised: 11 May 2026 | Accepted: 29 Jun 2026 | Published: 03 Jul 2026
Abstract
References
- 1.
Morris, Z.S.; Wooding, S.; Grant, J. The answer is 17 years, what is the question: Understanding time lags in translational research. J. R. Soc. Med. 2011, 104, 510–520. https://doi.org/10.1258/jrsm.2011.110180.
- 2.
Liang, Y.; Marincola, F.M. Translational Insights: A Paradigm Reversal in Translational Research. Transl. Insights 2026, 1, 1.
- 3.
Paul, S.M.; Mytelka, D.S.; Dunwiddie, C.T.; et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9, 203–214. https://doi.org/10.1038/nrd3078.
- 4.
Brown, D.G.; Wobst, H.J.; Kapoor, A.; et al. Clinical development times for innovative drugs. Nat. Rev. Drug Discov. 2022, 21, 793–794. https://doi.org/10.1038/d41573-021-00190-9.
- 5.
Wouters, O.J.; McKee, M.; Luyten, J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA 2020, 323, 844–853. https://doi.org/10.1001/jama.2020.1166.
- 6.
Schlander, M.; Hernandez-Villafuerte, K.; Cheng, C.Y.; et al. How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. Pharmacoeconomics 2021, 39, 1243–1269. https://doi.org/10.1007/s40273-021-01065-y.
- 7.
Boccardi, M. Translational process. J. Transl. Med. 2023, 21, 677. https://doi.org/10.1186/s12967-023-04507-7.
- 8.
Minisman, G.; Bhanushali, M.; Conwit, R.; et al. Implementing clinical trials on an international platform: Challenges and perspectives. J. Neurol. Sci. 2012, 313, 1–6. https://doi.org/10.1016/j.jns.2011.10.004.
- 9.
Hung, M.; Mohajeri, A.; Almpani, K.; et al. Successes and Challenges in Clinical Trial Recruitment: The Experience of a New Study Team. Med. Sci. 2024, 12, 39. https://doi.org/10.3390/medsci12030039.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Suite 4002 Level 4, 447 Collins Street, Melbourne, Victoria 3000, Australia
General Inquiries: info@sciltp.com